JP2020505334A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505334A5
JP2020505334A5 JP2019537154A JP2019537154A JP2020505334A5 JP 2020505334 A5 JP2020505334 A5 JP 2020505334A5 JP 2019537154 A JP2019537154 A JP 2019537154A JP 2019537154 A JP2019537154 A JP 2019537154A JP 2020505334 A5 JP2020505334 A5 JP 2020505334A5
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
antibody according
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537154A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128191B2 (ja
JP2020505334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012479 external-priority patent/WO2018129248A1/en
Publication of JP2020505334A publication Critical patent/JP2020505334A/ja
Publication of JP2020505334A5 publication Critical patent/JP2020505334A5/ja
Priority to JP2022130651A priority Critical patent/JP7461420B2/ja
Application granted granted Critical
Publication of JP7128191B2 publication Critical patent/JP7128191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537154A 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物 Active JP7128191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130651A JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130651A Division JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020505334A JP2020505334A (ja) 2020-02-20
JP2020505334A5 true JP2020505334A5 (enExample) 2021-02-04
JP7128191B2 JP7128191B2 (ja) 2022-08-30

Family

ID=62789396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537154A Active JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗IgE抗体並びにその方法及び組成物
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗IgE抗体並びにその方法及び組成物

Country Status (6)

Country Link
US (2) US11518818B2 (enExample)
EP (1) EP3565587A4 (enExample)
JP (2) JP7128191B2 (enExample)
AU (1) AU2018205484B2 (enExample)
CA (1) CA3049967C (enExample)
WO (1) WO2018129248A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
CN1418222A (zh) 2000-01-14 2003-05-14 第一制药株式会社 新的肽以及使用该肽的筛选方法
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2407485T1 (sl) * 2003-02-01 2016-09-30 Tanox, Inc. Visoko afinitetna anti-humana protitelesa IgE
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
EP2511299A1 (en) * 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック, インコーポレイテッド 抗ig−em1’抗体およびそれを用いる方法
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
TWI542598B (zh) * 2014-06-17 2016-07-21 中央研究院 交聯B淋巴球之CD23但不致敏肥大細胞的人源化抗-IgE抗體
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Similar Documents

Publication Publication Date Title
CN111601825A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
WO2008134659A3 (en) Antagonists to il-17a, il-17f, and il-23p19 and methods of use
JP2018537415A5 (enExample)
WO2018226580A3 (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR METHODS OF USE
CN115943162A (zh) 抗Claudin18.2抗体以及其用途
JP2007525465A5 (enExample)
JP2011184466A5 (enExample)
JP2015212284A5 (enExample)
BRPI0617485B8 (pt) anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
HK1221964A1 (zh) 与pd-1结合的抗原结合蛋白
JP2018526970A5 (enExample)
HRP20230197T1 (hr) Nosači za dostavu izvedeni iz omotača adenovirusnog proteina
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
JP2011501176A5 (enExample)
WO2007036745A3 (en) Interleukin-13 antibody composition
WO2010018378A8 (en) Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy
WO2011003100A4 (en) Compositions and methods for diagnosing and/or treating influenza infection
NO20092671L (no) Antistoffer mot human cytomegalovirus (HCMV)
JP2016512214A5 (enExample)
Haeusler et al. Evolutionary reversals of limb proportions in early hominids? Evidence from KNM-ER 3735 (Homo habilis)
JP2020505334A5 (enExample)
JP2017538412A5 (enExample)